Home > Oncology > ASCO 2022 > Trabectedin not superior to chemotherapy in recurrent epithelial ovarian cancer

Trabectedin not superior to chemotherapy in recurrent epithelial ovarian cancer

Presented By
Dr Domenica Lorusso, Catholic University of Sacred Heart, Italy
Conference
ASCO 2022
Trial
Phase 3, MIT023
Trabectedin failed to show a clinical benefit over standard-of-care chemotherapy in patients with BRCA mutated or BRCAness phenotype recurrent epithelial ovarian cancer. Nonetheless, translational studies are ongoing to identify potential predictive biomarkers of response to trabectedin. Trabectedin in combination with pegylated liposomal doxorubicin (PLD) is an approved treatment for patients with platinum-sensitive recurrent ovarian cancer [1]. Dr Domenica Lorusso (Catholic University of Sacred Heart, Italy) presented the phase 3 MIT023 trial results which assessed the efficacy and safety of trabectedin in patients with BRCA mutated or BRCAness phenotype recurrent epithelial ovarian cancer. In total, 244 patients were randomised 1:1 to trabectedin or investigator’s choice chemotherapy. The primary endpoint was overall survival (OS). After a median follow-up of 18.8 months, trabectedin failed to demonstrate an OS benefit over chemotherapy (15.8 mon...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on